

# Katrina G Millard

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8257074/katrina-g-millard-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21  
papers

4,164  
citations

17  
h-index

27  
g-index

27  
ext. papers

6,340  
ext. citations

34.1  
avg, IF

5.38  
L-index

#	Paper	IF	Citations
21	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , <b>2020</b> , 584, 437-442	50.4	1167
20	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , <b>2021</b> , 592, 616-622	50.4	730
19	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , <b>2021</b> , 591, 639-644	50.4	652
18	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , <b>2020</b> , 182, 828-842.e16	56.2	485
17	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , <b>2018</b> , 561, 479-484	50.4	250
16	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , <b>2021</b> , 595, 426-431	50.4	247
15	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , <b>2018</b> , 24, 1701-1707	50.5	142
14	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , <b>2021</b> , 54, 1853-1868.e7	32.3	83
13	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , <b>2021</b> ,	50.4	69
12	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals <b>2020</b> ,		60
11	Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 2311-2324	16.6	55
10	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants <b>2021</b> ,		54
9	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0219142	3.7	33
8	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	32
7	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies <b>2020</b> ,		30
6	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies <b>2021</b> ,		24
5	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year <b>2021</b> ,		19

4	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , <b>2022</b> ,	50.4	14
3	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
2	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. <b>2022</b> ,		3
1	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.. <i>Lancet Microbe, The</i> , <b>2022</b> , 3, e203-e214	22.2	2